Wash. Woman Claims Long-Term Gabapentin Use Caused Cognitive Problems

A Washington woman sued Pfizer, alleging long-term use of gabapentin caused cognitive issues. The plaintiff claims Pfizer knew of risks but concealed them. The case was filed in U.S. District Court for the Eastern District of Washington.

Original reporting
Published Nov 19, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wash. Woman Claims Long-Term Gabapentin Use Caused Cognitive Problems — source image
Decision brief

The 30-second read

$PFEBearishLow
01

Why it matters

If the claims gain traction, they can increase perceived litigation exposure and potentially trigger additional scrutiny of safety communications, though the article provides no settlement, damages, or regulatory action.

02

Market read

This is a company-specific legal overhang item for Pfizer, but without quantified financial impact or a procedural milestone, it is unlikely to drive a major repricing by itself.

03

What to watch

Traders may overreact to allegations; the market impact typically depends on whether similar cases are already priced in, the procedural posture (dismissal/MDL), and any contemporaneous FDA label or safety-communication updates.

Relevance 4/10Novelty 4/10Timing: today, as a newly filed lawsuit becomes part of the ongoing litigation overhang

Background

The piece describes a Washington state plaintiff suing Pfizer in federal court, alleging gabapentin’s long-term use caused cognitive effects and that Pfizer knew of the risks for decades.

Company-level read

Ticker impact

$PFEBearishMedium confidence
Context

Pfizer is named as the defendant in a lawsuit alleging long-term gabapentin use caused cognitive problems and that Pfizer concealed risks from doctors and the public.

Expected impact

Likely downside pressure as markets price in higher litigation and regulatory scrutiny risk tied to gabapentin.

Evidence & confidence

The article is a first-report style lawsuit filing naming Pfizer, which can drive incremental risk premium even without an announced settlement or quantified damages.

Market effects

Adds to broader scrutiny of gabapentinoid safety communications and product-liability risk across large pharma.

Primarily US-focused legal/regulatory overhang for Pfizer.

Moderate, as gabapentin safety and labeling disputes can resonate internationally even if the filing is US-based.

Counterpoint

A single pro se complaint may not materially change Pfizer’s near-term fundamentals unless it leads to major discovery, consolidated MDL movement, or a quantified settlement.

Key entities

  • Pfizer Inc.

    Named defendant accused of concealing gabapentin cognitive-risk information.

  • Anne McBride

    Plaintiff alleging cognitive problems after long-term gabapentin use.

  • U.S. District Court for the Eastern District of Washington

    Venue where the complaint was filed.

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$PFEMed

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

Pfizer has signed an exclusive licensing deal with China's Starna Therapeutics for three CAR-T therapies targeting autoimmune diseases, potentially worth up to $2.6 billion. Pfizer will pay $330 million upfront and additional milestone payments. The therapies are in early stages, with no human trials yet. This deal is part of Pfizer's strategy to boost growth by 2028 amid patent expirations and declining COVID-related revenue.

$PFEMed

Pfizer pays $330 million for Starna's CAR-T programs

Pfizer (PFE) licensed three pre-IND CAR-T programs from Starna Therapeutics for autoimmune diseases, paying $330M upfront. Starna may earn $2.3B in milestones plus royalties. Pfizer gains rights to Starna's in vivo CAR-T tech for inflammation, immunology, and oncology.

$PFEMed

Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

Pfizer (PFE) has signed an exclusive licensing deal with Starna Therapeutics to develop and commercialize CAR-T therapies, potentially worth up to $2.6B. The agreement covers the development and commercialization of these therapies, with Pfizer leading the efforts. This partnership aims to advance cancer treatments using RNA medicines.